The tweet was deleted by the author.
But we saved everything 🙂.
Taysha Gene Therapies has provided an update on its TSHA-102 program, which is currently under clinical evaluation for Rett syndrome. The announcement was made following the company's participation at the 55th Child Neurology Society Annual Meeting.
The company used the event as a forum to share recent developments and connect with clinicians, researchers, and advocates in the pediatric neurology community.
View post on X Loading...
Taysha Gene Therapies has earlier discussed clinical advancements of its TSHA-102 gene therapy at the CNSAM event with the neurology community, as reported here. The company also featured multiple encore presentations on TSHA-102 for Rett syndrome at the Child Neurology Society Annual Meeting, according to previous coverage. These activities highlight ongoing engagement with clinicians and researchers on TSHA-102’s clinical progress.